Eleven years later, following the then recent approval of the GLP-1 receptor agonist exendin-4 for the treatment of type 2 diabetes [61], exendin-4 was given in a small retrospective study in SBS patients [62]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.